Piper Jaffray Reiterates Overweight Rating On OMCL

Piper Jaffray has reported a maintained Overweight Rating on Omnicell Inc. OMCL. According to Piper Jaffray, "Proposed Stage 2 Meaningful Use requirements require automated tracking of 30% of medication orders, which we believe will be a catalyst for the sale of automated medication dispensing cabinets. Quantifying this opportunity based on a top-down model, we see 25% upside to FY12 consensus. We anticipate further clarity when the HHS issues final stage 2 requirements this summer. We are buyers here; reiterate Overweight rating, $17 target." OMCL closed at $13.94 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care TechnologyOmnicell Inc.Piper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!